BCAX Valuation

Bicara Therapeutics Inc

Add to Watchlist

Advanced Chart

11.310

+0.07(0.623%)1D

Overview
Forecast
Valuation
Earnings

BCAX Relative Valuation

BCAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCAX is overvalued; if below, it's undervalued.

Historical Valuation

Bicara Therapeutics Inc (BCAX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.73. The fair price of Bicara Therapeutics Inc (BCAX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：11.31

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.30

P/B

Median3y

1.04

Median5y

1.04

-14.82

FCF Yield

Median3y

-8.77

Median5y

-8.77

Competitors Valuation Multiple

The average P/S ratio for BCAX's competitors is 25.45, providing a benchmark for relative valuation. Bicara Therapeutics Inc Corp (BCAX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BCAX.O

Bicara Therapeutics Inc

Loss

Average P/S: 25.45

612.99M